DGAP-News
Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - Seite 2
About Indatuximab Ravtansine (BT-062)
Indatuximab Ravtansine (BT-062) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody and a highly potent cytotoxic maytansine derivative (DM4) using the ADC technology developed
by ImmunoGen, Inc. The antibody binds specifically to the antigen CD138, which is over-expressed on multiple myeloma cells and a variety of solid tumors.
Once the conjugate is internalized into the target cell, the DM4 is released from the targeting molecule, thereby releasing it in its fully-potent state. This combination of high efficacy and
specificity with low systemic toxicity sets BT-062 apart from most therapies currently used to treat multiple myeloma.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily
in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used
for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are
produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart
Lesen Sie auch
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These
statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of
actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.